Skip to main content

Advertisement

SpringerLink
Log in

Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy

  • Published:
Journal of Cancer Survivorship Aims and scope Submit manuscript

Abstract

Purpose

Ototoxicity is a prominent side effect of cisplatin-based chemotherapy. There are few reports, however, estimating its prevalence in well-defined cohorts and associated risk factors.

Methods

Testicular cancer (TC) survivors given first-line cisplatin-based chemotherapy completed validated questionnaires. Descriptive statistics evaluated the prevalence of ototoxicity, defined as self-reported hearing loss and/or tinnitus. We compared patients with and without tinnitus or hearing loss using Chi-square test, two-sided Fisher’s exact test, or two-sided Wilcoxon rank sum test. To evaluate ototoxicity risk factors, a backward selection logistic regression procedure was performed.

Results

Of 145 TC survivors, 74% reported ototoxicity: 68% tinnitus; 59% hearing loss; and 52% reported both. TC survivors with tinnitus were more likely to indicate hypercholesterolemia (P = 0.008), and difficulty hearing (P < .001). Tinnitus was also significantly related to age at survey completion (OR = 1.79; P = 0.003) and cumulative cisplatin dose (OR = 5.17; P < 0.001). TC survivors with hearing loss were more likely to report diabetes (P = 0.042), hypertension (P = 0.007), hypercholesterolemia (P < 0.001), and family history of hearing loss (P = 0.044). Risk factors for hearing loss included age at survey completion (OR = 1.57; P = 0.036), hypercholesterolemia (OR = 3.45; P = 0.007), cumulative cisplatin dose (OR = 1.94; P = 0.049), and family history of hearing loss (OR = 2.87; P = 0.071).

Conclusions

Ototoxicity risk factors included age, cisplatin dose, cardiovascular risk factors, and family history of hearing loss. Three of four TC survivors report some type of ototoxicity; thus, follow-up of cisplatin-treated survivors should include routine assessment for ototoxicity with provision of indicated treatments.

Implications for Cancer Survivors

Survivors should be aware of risk factors associated with ototoxicity. Referrals to audiologists before, during, and after cisplatin treatment is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on request.

References

  1. Ader DN. Developing the patient-reported outcomes measurement information system (PROMIS). Med Care. 2007;45(5):S1–2. https://doi.org/10.1097/01.mlr.0000260537.45076.74.

    Article  Google Scholar 

  2. American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf

  3. Ardeshirrouhanifard S, Fossa SD, Huddart R, Monahan PO, Fung C, Song Y, Dolan ME, Feldman DR, Hamilton RJ, Vaughn D, Martin NE, Kollmannsberger C, Dinh P, Einhorn L, Frisina RD, Travis LB. Ototoxicity after cisplatin-based chemotherapy: factors associated with discrepancies between patient-reported outcomes and audiometric assessments. Ear Hear. 2022. https://doi.org/10.1097/AUD.0000000000001172.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TA, Tervonen H, Thursfield V, Ransom D, Shack L, Woods RR, Turner D, Leonfellner S, Ryan S, Saint-Jacques N, De P, McClure C, Ramanakumar AV, Stuart-Panko H, . . . Bray F. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11), 1493-1505. https://doi.org/10.1016/S1470-2045(19)30456-5

  5. Arnold ML, Hyer K, Chisolm T. Medicaid hearing aid coverage for older adult beneficiaries: a state-by-state comparison. Health Aff (Millwood). 2017;36(8):1476–84. https://doi.org/10.1377/hlthaff.2016.1610.

    Article  PubMed  Google Scholar 

  6. Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. Cisplatin-based chemotherapy: add high-frequency audiometry in the regimen. Indian J Cancer. 2009;46(4):311–7. https://doi.org/10.4103/0019-509X.55551.

    Article  CAS  PubMed  Google Scholar 

  7. ASCO, A. S. o. C. O. Long-term side effects of cancer treatment. 2019. https://www.cancer.net/survivorship/long-term-side-effects-cancer-treatment. Accessed 09/2019.

  8. Besser J, Stropahl M, Urry E, Launer S. Comorbidities of hearing loss and the implications of multimorbidity for audiological care. Hear Res. 2018;369:3–14. https://doi.org/10.1016/j.heares.2018.06.008.

    Article  PubMed  Google Scholar 

  9. Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, Hall MD, Amable L, Cunningham LL. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017;8(1). https://doi.org/10.1038/s41467-017-01837-1.

  10. Carabellese C, Appollonio I, Rozzini R, Bianchetti A, Frisoni GB, Frattola L, Trabucchi M. Sensory impairment and quality of life in a community elderly population. J Am Geriatr Soc. 1993;41(4):401–7.

    Article  CAS  PubMed  Google Scholar 

  11. Chia EM, Wang JJ, Rochtchina E, Cumming RR, Newall P, Mitchell P. Hearing impairment and health-related quality of life: the Blue Mountains Hearing Study. Ear Hear. 2007;28(2):187–95 (PM:17496670).

    Article  PubMed  Google Scholar 

  12. Chisolm TH, Johnson CE, Danhauer JL, Portz LJP, Abrams HB, Lesner S, McCarthy PA, Newman CW. A systematic review of health-related quality of life and hearing aids: final report of the American Academy of Audiology Task Force on the health-related quality of life benefits of amplification in adults. J Am Acad Audiol. 2007;18(02):151–83. https://doi.org/10.3766/jaaa.18.2.7.

    Article  PubMed  Google Scholar 

  13. Choi JS, Betz J, Li L, Blake CR, Sung YK, Contrera KJ, Lin FR. Association of using hearing aids or cochlear implants with changes in depressive symptoms in older adults. JAMA Otolaryngol-Head Neck Surg. 2016;142(7):652–7.

    Article  PubMed  Google Scholar 

  14. Cianfrone G, Pentangelo D, Cianfrone F, Mazzei F, Turchetta R, Orlando M, Altissimi G. Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur Rev Med Pharmacol Sci. 2011;15(6):601–36.

    CAS  PubMed  Google Scholar 

  15. Clark J. Uses and abuses of hearing loss classification. ASHA. 1981;23:493–500.

    CAS  PubMed  Google Scholar 

  16. Cruickshanks K, Klein R, Klein B, et al. Cigarette smoking and hearing loss: the epidemiology of hearing loss study. JAMA. 1998;279(21):1715–9.

    Article  CAS  PubMed  Google Scholar 

  17. Dalton DS, Cruickshanks KJ, Klein BE, Klein R, Wiley TL, Nondahl DM. The impact of hearing loss on quality of life in older adults. Gerontologist. 2003;43(5):661–8 (PM:14570962).

    Article  PubMed  Google Scholar 

  18. Dawes P, Cruickshanks KJ, Fischer ME, Klein BEK, Klein R, Nondahl DM. Hearing-aid use and long-term health outcomes: hearing handicap, mental health, social engagement, cognitive function, physical health, and mortality. Int J Audiol. 2015;54(11):838–44. https://doi.org/10.3109/14992027.2015.1059503.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Deal JA, Reed NS, Kravetz AD, Weinreich H, Yeh C, Lin FR, Altan A. Incident hearing loss and comorbidity. JAMA Otolaryngol-Head Neck Surg. 2019;145(1):36. https://doi.org/10.1001/jamaoto.2018.2876.

    Article  PubMed  Google Scholar 

  20. Driscoll C, Beswick R, Doherty E, D’Silva R, Cross A. The validity of family history as a risk factor in pediatric hearing loss. Int J Pediatr Otorhinolaryngol. 2015;79(5):654–9. https://doi.org/10.1016/j.ijporl.2015.02.007.

    Article  PubMed  Google Scholar 

  21. Dutta A, Venkatesh MD, Kashyap RC. Study of the effects of chemotherapy on auditory function. Indian J Otolaryngol Head Neck Surg. 2005;57(3):226–8. https://doi.org/10.1007/BF03008019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC, Frisina RD, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Gamazon ER, Cox NJ, Huddart R, Ardeshir-Rouhani-Fard S, Monahan P, . . . Dolan ME. Clinical and genome-wide analysis of cisplatin-induced tinnitus implicates novel ototoxic mechanisms. Clin Cancer Res. 2019;25(13):4104-4116. https://doi.org/10.1158/1078-0432.ccr-18-3179.

  23. EsfahaniMonfared Z, Khosravi A, SafaviNaini A, Radmand G, Khodadad K. Analysis of cisplatin-induced ototoxicity risk factors in iranian patients with solid tumors: a cohort, prospective and single institute study. Asian Pac J Cancer Prev. 2017;18(3):753–8. https://doi.org/10.22034/APJCP.2017.18.3.753.

    Article  Google Scholar 

  24. FDA Center for Drug Evaluation and Research. FDA Label for Sodium Thiosulfate Injection [9/20/2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203923Orig1s000Lbl.pdf.

  25. Febles NK, Bauer MA, Ding B, Zhu X, Gallant ND, Frisina RD. A combinatorial approach to protect sensory tissue against cisplatin-induced ototoxicity. Hear Res. 2022;415:108430. https://doi.org/10.1016/j.heares.2022.108430.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Fennec Pharmaceuticals. Fennec pharmaceuticals receives fast track designation by FDA for Pedmark Research Triangle Park, NC [March 21, 2018]. Available from: http://fennecpharma.com/fennec-pharmaceuticals-receives-fast-track-designation-by-fda-for-pedmark/.

  27. Food & Drug Administration. Docket No. FDA-2021-N-0862; Nonprescription Drug Product with an Additional Condition for Nonprescription Use. Website: Federal Register: Nonprescription Drug Product With an Additional Condition for Nonprescription Use. (2022; last viewed June 27, 2022).

  28. Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, Pollock BH, Ramdas J, Lange B, Van Hoff D, VanSoelen ML, Wiernikowski J, Neuwelt EA, Sung L. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63–74.

    Article  CAS  PubMed  Google Scholar 

  29. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, Monahan PO, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Budnick A, Johnson EM, Ardeshir-Rouhani-Fard S, Einhorn LH, Lipshultz SE, Dolan ME, Travis LB. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712–20. https://doi.org/10.1200/jco.2016.66.8822.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fung C, Sesso HD, Williams AM, Kerns SL, Monahan P, Abu Zaid M, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Kollmannsberger CK, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Lipshultz SE, Einhorn LH, Fossa SD, Travis LB. Multi-institutional assessment of adverse health outcomes among North American testicular cancer survivors after modern cisplatin-based chemotherapy. J Clin Oncol. 2017;35(11):1211–22. https://doi.org/10.1200/jco.2016.70.3108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Guthrie O, Spankovich C (TBD) Emerging and established therapies for chemotherapy-induced ototoxicity. J Cancer Survivorship

  32. Hanna NH, Einhorn LH. Testicular cancer — discoveries and updates. N Engl J Med. 2014;371(21):2005–16. https://doi.org/10.1056/nejmra1407550.

    Article  PubMed  Google Scholar 

  33. Haugnes HS, Stenklev NC, Brydoy M, Dahl O, Wilsgaard T, Laukli E, Fossa SD. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncol. 2018;57(8):1075–83. https://doi.org/10.1080/0284186X.2018.1433323.

    Article  CAS  PubMed  Google Scholar 

  34. Henry JA, Thielman EJ, Zaugg TL, Kaelin C, Schmidt CJ, Griest S, McMillan GP, Myers P, Rivera I, Baldwin R, Carlson K. Randomized controlled trial in clinical settings to evaluate effectiveness of coping skills education used with progressive tinnitus management. J Speech Lang Hear Res. 2017;60(5):1378–97. https://doi.org/10.1044/2016_JSLHR-H-16-0126.

  35. Holman JA, Drummond A, Naylor G. The effect of hearing loss and hearing device fitting on fatigue in adults: a systematic review. Ear Hear. 2021;42(1):1–11. https://doi.org/10.1097/AUD.0000000000000909.

    Article  PubMed  Google Scholar 

  36. Isherwood B, Gonçalves AC, Cousins R, Holme R. The global hearing therapeutic pipeline:2021. Drug Discov Today. 2021. https://doi.org/10.1016/j.drudis.2021.11.009.

    Article  PubMed  Google Scholar 

  37. Joo Y, Cruickshanks KJ, Klein BEK, Klein R, Hong O, Wallhagen MI. The contribution of ototoxic medications to hearing loss among older adults. J Gerontol: Series A. 2020;75(3):561–6. https://doi.org/10.1093/gerona/glz166.

    Article  Google Scholar 

  38. Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, Stump TE, Sesso HD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard C, Huddart RA, Kim J, Kollmannsberger C, Sahasrabudhe DM, Cook R, Fossa SD, Einhorn LH, Travis LB. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J Clin Oncol. 2018;36(15):1505–12. https://doi.org/10.1200/jco.2017.77.0735.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kitterick PT, Ferguson MA. Hearing aids and health-related quality of life in adults with hearing loss. JAMA. 2018;319(21):2225–6. https://doi.org/10.1001/jama.2018.5567.

    Article  PubMed  Google Scholar 

  40. Knight K, Kraemer D, Neuwelt E. Ototoxicity in children receiving platinum chemotherapy: understanding a commonly occuring toxicity that may influance academic and social development. J Clin Oncol. 2005;23(34):8588–96.

    Article  PubMed  Google Scholar 

  41. Knight K, Kraemer D, Winter C, et al. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25:1190–5.

    Article  CAS  PubMed  Google Scholar 

  42. Kumar A, Gulati R, Singhal S, Hasan A, Khan A. The effect of smoking on the hearing status-a hospital based study. J Clin Diagn Res. 2013;7(2):210–4. https://doi.org/10.7860/jcdr/2013/4968.2730.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Landier W. Ototoxicity and cancer therapy. Cancer. 2016;122(11):1647–58. https://doi.org/10.1002/cncr.29779.

    Article  PubMed  Google Scholar 

  44. Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales—a report from the Children’s Oncology Group. J Clin Oncol. 2014;32(6):527–34. https://doi.org/10.1200/jco.2013.51.2038.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Lee H, Kang D, Yeo S, Kim S. Hearing aid effects and satisfaction in patients with tinnitus. J Clin Med. 2022;11(4):1096. https://doi.org/10.3390/jcm11041096.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Lin FR. Hearing loss and cognition among older adults in the United States. J Gerontol A Biol Sci Med Sci. 2011;66A(10):1131–6. https://doi.org/10.1093/gerona/glr115.

    Article  PubMed Central  Google Scholar 

  47. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivimäki M, Larson EB, Ogunniyi A, . . . Mukadam N. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413-446. https://doi.org/10.1016/s0140-6736(20)30367-6

  48. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, . . . Mukadam N. Dementia prevention, intervention, and care. The Lancet. 2017;390(10113):2673–2734. https://doi.org/10.1016/S0140-6736(17)31363-6.

  49. Loughrey DG, Kelly ME, Brennan S, Lawlor BA. Association of age-related hearing loss with cognitive function, cognitive impairment, and dementia: a systematic review and meta-analysis. JAMA Otolaryngol-Head & Neck Surg. 2018;144(2):115–26. https://doi.org/10.1001/jamaoto.2017.2513.

    Article  Google Scholar 

  50. Martin SS, and Cardoso R. BMJ Best Practice: Hypercholesterolemia. BMJ Publishing Group 2022. 2021. Retrieved Aug 8 from https://bestpractice.bmj.com/topics/en-us/170.

  51. Marshak T, Steiner M, Kaminer M, Levy L, Shupak A. Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a randomized controlled study. Otolaryngol Head Neck Surg. 2014;150(6):983–90.

    Article  PubMed  Google Scholar 

  52. McMahon CM, Kifley A, Rochtchina E, Newall P, Mitchell P. The contribution of family history to hearing loss in an older population. Ear Hear. 2008;29(4):578–84. https://doi.org/10.1097/AUD.0b013e31817349d6.

    Article  PubMed  Google Scholar 

  53. Mick P, Kawachi I, Lin FR. The association between hearing loss and social isolation in older adults. Otolaryngol-Head and Neck Surg. 2014;150(3):378–84. https://doi.org/10.1177/0194599813518021.

    Article  Google Scholar 

  54. Mulrow CD, Aguilar C, Endicott JE, Velez R, Tuley MR, Charlip WS, Hill JA. Association between hearing impairment and the quality of life of elderly individuals. J Am Geriatr Soc. 1990;38(1):45–50.

    Article  CAS  PubMed  Google Scholar 

  55. Nekhlyudov L, Ganz PA, Arora NK, Rowland JH. Going beyond being lost in transition: a decade of progress in cancer survivorship. J Clin Oncol. 2017;35(18):1978–81. https://doi.org/10.1200/jco.2016.72.1373.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Oldenburg J, Fosså SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 2006;15(5):791–800. https://doi.org/10.1007/s11136-005-5370-6.

    Article  PubMed  Google Scholar 

  57. Paken J, Govender CD, Pillay M, Ayele BT, Sewram V. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa. BMC Cancer. 2021;21(1):822. https://doi.org/10.1186/s12885-021-08567-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-associated ototoxicity: a review for the health professional. J Toxicol. 2016;2016:1809394. https://doi.org/10.1155/2016/1809394.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Paken J, Govender CD and Sewram V. Research protocol: cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program. BMC Women's Health. 2017;17(1). https://doi.org/10.1186/s12905-017-0486-8.

  60. Pearson SE, Taylor J, Patel P, Baguley DM. Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review. Int J Audiol. 2019;58(11):685–95. https://doi.org/10.1080/14992027.2019.1660918.

    Article  PubMed  Google Scholar 

  61. Pharmaceuticals F. Fennec pharmaceuticals announces commercial availability of PEDMARK (sodium thiosulfate injection) in the United States. 2022. https://investors.fennecpharma.com/news-releases/news-release-details/fennec-pharmaceuticals-announces-commercial-availability. Accessed 17 Oct 2022.

  62. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. European J Cancer. 2005;41(8):1135–9. https://doi.org/10.1016/j.ejca.2005.02.012.

    Article  CAS  Google Scholar 

  63. Pronk M, Deeg DJ, Smits C, Twisk JW, van Tilburg TG, Festen JM, Kramer SE. Hearing loss in older persons: does the rate of decline affect psychosocial health? J Aging Health. 2014;26(5):703–23.

    Article  PubMed  Google Scholar 

  64. Reed NS, Altan A, Deal JA, Yeh C, Kravetz AD, Wallhagen M, Lin FR. Trends in health care costs and utilization associated with untreated hearing loss over 10 years. JAMA Otolaryngol Head Neck Surg. 2019;145(1):27–34. https://doi.org/10.1001/jamaoto.2018.2875.

    Article  PubMed  Google Scholar 

  65. dos Santos NAG, Ferreira RS, dos Santos AC. Overview of cisplatin-induced neurotoxicity and ototoxicity and the protective agents. Food Chem Toxicol. 2020;136:111079. https://doi.org/10.1016/j.fct.2019.111079.

    Article  CAS  PubMed  Google Scholar 

  66. Schacht J, Talaska AE, Rybak LP. Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec Adv Integr Anat Evol Biol. 2012;295(11):1837–50. https://doi.org/10.1002/ar.22578.

    Article  CAS  Google Scholar 

  67. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003;104(4):488–95. https://doi.org/10.1002/ijc.10981.

    Article  CAS  PubMed  Google Scholar 

  68. Shargorodsky J, Curhan SG, Eavey R, Curhan GC. A prospective study of cardiovascular risk factors and incident hearing loss in men. Laryngoscope. 2010;120(9):1887–91. https://doi.org/10.1002/lary.21039.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Shekhawat GS, Searchfield GD, Stinear CM. Role of hearing aids in tinnitus intervention: a scoping review. J Am Acad Audiol. 2013;24(08):747–62. https://doi.org/10.3766/jaaa.24.8.11.

    Article  PubMed  Google Scholar 

  70. Skalleberg J, Smastuen MC, Oldenburg J, Osnes T, Fossa SD, Bunne M. The relationship between cisplatin-related and age-related hearing loss during an extended follow-up. Laryngoscope. 2020;130(9):E515–21. https://doi.org/10.1002/lary.28543.

    Article  CAS  PubMed  Google Scholar 

  71. Stark P, Hickson L. Outcomes of hearing aid fitting for older people with hearing impairment and their significant others. Int J Audiol. 2004;43(7):390–8. https://doi.org/10.1080/14992020400050050.

    Article  PubMed  Google Scholar 

  72. Strawbridge WJ, Wallhagen MI, Shema SJ, Kaplan GA. Negative consequences of hearing impairment in old age: a longitudinal analysis. Gerontologist. 2000;40(3):320–6.

    Article  CAS  PubMed  Google Scholar 

  73. Sung YK, Li L, Blake C, Betz J, Lin FR. Association of hearing loss and loneliness in older adults. J Aging Health. 2015. https://doi.org/10.1177/0898264315614570.

    Article  PubMed  Google Scholar 

  74. Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, Chen Y, Zou Z. Cisplatin-induced ototoxicity: updates on molecular mechanisms and otoprotective strategies. European J Pharm Biopharm. 2021;163:60–71. https://doi.org/10.1016/j.ejpb.2021.03.008.

    Article  CAS  Google Scholar 

  75. Thomson RS, Auduong P, Miller AT, Gurgel RK. Hearing loss as a risk factor for dementia: a systematic review. Laryngoscope Invest Otolaryngol. 2017;2(2):69–79. https://doi.org/10.1002/lio2.65.

    Article  Google Scholar 

  76. Trendowski MR, Wheeler HE, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. Clinical and genome-wide analysis of multiple severe cisplatin-induced neurotoxicities in adult-onset cancer survivors. Clin Cancer Res. 2020;26(24):6550–8. https://doi.org/10.1158/1078-0432.ccr-20-2682.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT, Boekholdt SM, Nordestgaard BG, Stroes ESG. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39(27):2589–96. https://doi.org/10.1093/eurheartj/ehy334.

    Article  CAS  PubMed  Google Scholar 

  78. Vestergaard Knudsen L, Öberg M, Nielsen C, Naylor G, Kramer SE. Factors influencing help seeking, hearing aid uptake, hearing aid use and satisfaction with hearing aids: a review of the literature. Trends Amplif. 2010;14(3):127–54. https://doi.org/10.1177/1084713810385712.

    Article  Google Scholar 

  79. Viglietta V, Shi F, Hu Q-Y, Ren Y, Keilty J, Wolff H, McCarthy R, Kropp J, Weber P, Soglia J. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. Invest New Drugs. 2020;38(5):1463–71. https://doi.org/10.1007/s10637-020-00918-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Waissbluth S. Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: what do we know so far? Eur Arch Otorhinolaryngol. 2020;277(9):2413–22. https://doi.org/10.1007/s00405-020-06003-w.

    Article  PubMed  Google Scholar 

  81. Waissbluth S, Peleva E, Daniel SJ. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria. Eur Arch Otorhinolaryngol. 2017;274(3):1187–96. https://doi.org/10.1007/s00405-016-4117-z.

    Article  PubMed  Google Scholar 

  82. Weinstein BE, Ventry IM. Hearing impairment and social isolation in the elderly. J Speech Hear Res. 1982;25(4):593–9 (PM:7162161).

    Article  CAS  PubMed  Google Scholar 

  83. Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, Fossa SD, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Einhorn LH, Cox NJ, . . . Travis LB. Variants in <i>WFS1</i> and other mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin Cancer Res. 2017;23(13):3325–3333. https://doi.org/10.1158/1078-0432.ccr-16-2809

  84. Zhang X, Trendowski MR, Wilkinson E, Shahbazi M, Dinh PC, Shuey MM, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Huddart R, Martin NE, Sanchez VA, Frisina RD, Einhorn LH, Cox NJ, Travis LB, Dolan ME. Pharmacogenomics of cisplatin-induced neurotoxicities: hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022. https://doi.org/10.1002/cam4.4644.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Drs. Frisina, Dolan, Sesso, Dinh, Feldman, Monahan, and Travis were supported by 2 R01 CA157823 funded by the National Cancer Institute. Dr. Sanchez was supported by R01DC019408-01 funded by the National Institute of Deafness and Other Communication Disorders.

Author information

Authors and Affiliations

  1. Department of Otolaryngology-Head & Neck Surgery, University of South Florida, 12901 Bruce B. Downs Blvd., MDC 73, Tampa, FL, 33612, USA

    Victoria A. Sanchez

  2. Department of Medical Oncology, Indiana University, Indianapolis, IN, USA

    Paul C. Dinh Jr.

  3. College of Nursing, University of South Florida, Tampa, FL, USA

    Jennessa Rooker

  4. Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA

    Patrick O. Monahan, Sandra K. Althouse, Lawrence H. Einhorn & Lois B. Travis

  5. J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA

    Chunkit Fung

  6. Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA, USA

    Howard D. Sesso

  7. Department of Medicine, University of Chicago, Chicago, IL, USA

    M. Eileen Dolan

  8. Department of Medical Engineering, University of South Florida, Tampa, FL, USA

    Robert D. Frisina

Authors
  1. Victoria A. Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul C. Dinh Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jennessa Rooker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick O. Monahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sandra K. Althouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chunkit Fung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Howard D. Sesso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lawrence H. Einhorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Eileen Dolan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Robert D. Frisina
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lois B. Travis
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: LT, RF, VS; methodology: VS, PD, LT, PM, JR; formal analysis and investigation: PM, PD, LT, VS; writing—original draft preparation: VS, JR, LT; writing—review and editing: all authors; funding acquisition: LT; resources: LT; supervision: LT, RF.

Corresponding author

Correspondence to Victoria A. Sanchez.

Ethics declarations

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee at Indiana University. Informed consent was obtained from all participants in this study.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sanchez, V.A., Dinh, P.C., Rooker, J. et al. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy. J Cancer Surviv 17, 27–39 (2023). https://doi.org/10.1007/s11764-022-01313-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11764-022-01313-w

Keywords

Search

Navigation